A Multi-centre, Randomised, Placebo Controlled, Double Blinded, Multiple Dose Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects (Explorer3)

Trial Profile

A Multi-centre, Randomised, Placebo Controlled, Double Blinded, Multiple Dose Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects (Explorer3)

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Apr 2017

At a glance

  • Drugs Concizumab (Primary)
  • Indications Haemophilia A
  • Focus Adverse reactions
  • Acronyms Explorer3
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 01 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 20 Oct 2016 Status changed from recruiting to active, no longer recruiting.
    • 19 Oct 2016 Planned End Date changed from 1 Mar 2017 to 1 Oct 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top